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Abstract Leflunomide is a disease-modifying antirheumatic
drug with antiinflammatory and immunosuppressive activity
used for the treatment of psoriatic and rheumatoid arthritis. It
undergoes rapid metabolization to teriflunomide, a metabolite
that is responsible for the biological activity of leflunomide.
Continuing our investigations on the interactions of biologi-
cally important azahetarenes with the environment, we fo-
cused on leflunomide and its active metabolite, teriflunomide,
considering the interactions teriflunomide–amino acid within
the target protein (dihydroorotate dehydrogenase) using den-
sity functional theory, as well as ONIOM techniques. The
results of theoretical studies have shown that the interactions
of teriflunomide with tyrosine and arginine involve principally
the amide fragment of teriflunomide. The presence of the in-
ternal hydrogen bond between (Z)-teriflunomide carbonyl ox-
ygen and enolic hydroxyl decreases the interaction strength
between teriflunomide and tyrosine or arginine. Even the E
isomer of teriflunomide would usually provide a stronger in-
teraction teriflunomide—amino acid than the Z isomer with
the internal hydrogen bond.
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Introduction
Leflunomide 1 (Scheme 1) is a disease-modifying antirheu-
matic drug (DMARD) with antiinflammatory and immuno-
suppressive activity used for the treatment of psoriatic and
rheumatoid arthritis since 1998 (USA) and 1999 (EU) [1–3].
Leflunomide undergoes rapid metabolization to teriflunomide
2 (Scheme 1), a metabolite that is responsible for the biolog-
ical activity of leflunomide [4]. Teriflunomide 2 is a noncom-
petitive inhibitor of dihydroorotate dehydrogenase
(DHODH), an enzyme involved in the conversion of
dihydroorotate (DHO) to orotate by utilizing a flavin mono-
nucleotide (FMN) cofactor in the redox reaction present in the
pyrimidine de novo biosynthesis pathway. This leads to inhi-
bition of β-lymphocyte proliferation and immunomodulatory
effect. Moreover, teriflunomide 2 suppresses T-cell prolifera-
tion by blocking the synthesis of immunosuppressive cyto-
kines. Teriflunomide itself is used in the management of re-
lapsing multiple sclerosis as an oral drug [5, 6]. Due to its
interaction with the immune system, leflunomide 1 has also
been investigated for anticancer activity. It was shown that
leflunomide might be a potential new candidate for targeted
therapy in multiple myeloma [7] and, more recently, in neu-
roblastoma [8]. The pharmacological profile of leflunomide 1
seems to be an inspirational factor that stimulates many scien-
tific groups around the world for searching of new synthetic
methods of this drug as well as its analogues [9–13].
Albeit the detailed mechanism of leflunomide 1
metabolization is not known, the experimental studies indicat-
ed that the presence of unsubstituted C-3 position in the
isoxazole ring is crucial for the ring opening [4]. Most prob-
ably the ring cleavage occurs through a two-electron reduction
to an imine intermediate. The imine is further converted via a
P450-catalyzed dehydration to teriflunomide 2. The latter
compound can exist in two geometric forms, i.e., Z and E
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isomers, that can equilibriate through a keto form (Scheme 1).
The Z isomer is energetically favored due to the presence of an
internal hydrogen bond between the keto and hydroxyl group.
The existence of this bond is also helpful in the penetration of
teriflunomide through cell membranes but it is believed that
such bond interferes with the interaction of teriflunomide with
the target enzyme—DHODH.
The interaction of teriflunomide 2with DHODH has been a
subject of several investigations, both from the experimental
and theoretical point of view. Liu et al. [14] analyzed the
crystal structure of the teriflunomide–human DHODH com-
plex and found that teriflunomide 2 interacts with amino acids
Tyr356 and Arg136 in the enzyme domain. The carbonyl ox-
ygen is hydrogen bonded through a water molecule to
Arg136, whereas the enolic hydroxyl is directly linked to
Tyr356. In a more recent mostly docking studies, Leban
et al. as well as Davies et al. [15, 16] concluded that in the
2–HSDHODH complex, three hydrogen bonds could be ob-
served. Apart from the above direct bonding to Tyr365, there
are two water-mediated hydrogen contacts to Arg265 and
Gln47. From a comprehensive theoretical analysis of com-
pounds 1 and 2 as well as several teriflunomide analogues,
Panek et al. [17] inferred that the primary acceptors of the
external interactions are the amide and nitrile groups.
The interactions between drugmolecules and their environ-
ment can be investigated with a variety of analytical methods
including NMR, IR, Raman, mass, and scanning tunneling
spectroscopy (STS). Computational chemistry is an invalu-
able complement to nuclear magnetic resonance spectroscopy
as it allows for rapid visualization of the solvation phenomena.
We successfully applied the methodology that involve com-
putations and NMR for the estimation of interaction sites of an
indazole–magnesium complex [18]. These interactions are
important because of the relationship between magnesium
and oncogenesis [19]. Moreover, the 1H NMR technique,
compared to other methods, is fast and cheap, and enables to
follow changes in chemical shifts with no need for a time-
consuming alternative approach. Herein it must be added that
the use of 15N or 17O NMR techniques would result in serious
errors and could not be such informative as there are only two
nitrogen and oxygen atoms in the structure of 1 and 2. More-
over, very low natural abundance and a relatively large quad-
rupole moment renders 17O NMRmethod difficult for routine
NMR measurements. The first drawback is relevant to 15N
NMR as well. This substantiates once more the assumption
that the use of proton NMR spectroscopy is the most appro-
priate for the studies described in the present paper. However,
the investigations and understanding of the relationship be-
tween molecular structure and NMR parameters can some-
times be quite difficult, and therefore are often supported by
theoretical calculations [17, 18]. Applications of in silico tech-
niques are very wide, e.g., the DFTcalculations at the B3LYP/
6-31G level of theory were recently used to study leflunomide
adsorption to nanotubes [20]. The approach that involves
computations and 1H NMR spectroscopy for the estimation
of interaction sites of analyte able to affect the environment
seems to be a right choice. On this account we decided to
extend the goal of our study to investigate the NMR spectrum
Scheme 1 Mechanism of
leflunomide 1 metabolization
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of the pro-drug 1, especially the influence of solvent mole-
cules on amide moiety within cell. Then, we focused our at-
tention on the interactions of active metabolite, teriflunomide
2, with selected amino acids in the enzymatic binding site of
DHODH. To validate conclusions, we carried out an ONIOM
analysis to confirm the results of the DFT investigation, espe-
cially that, to the authors’ knowledge, there have been no prior
studies of teriflunomide and DHODH using the ONIOM
technique.
Results and discussion
Continuing our investigations on the interactions of biologi-
cally important azahetarenes with environment, we focused
on leflunomide and its active metabolite, teriflunomide. The
present study deals, inter alia, with simulation of the 1H NMR
spectrum of 1. Particular attention was given to the amide
bond and isoxazole ring in the first solvation sphere. The
obtained results were correlated with the experimental data
of Faragher et al. [21]. Furthermore, we estimated the interac-
tion energy of teriflunomide 2 with tyrosine and, through a
water molecule, with arginine, both in the enzymatic binding
site. To achieve the above aims, we performed a geometric
analysis usingGaussian G09 D.01 suite [22]. The conformers
were obtained by rotating the bonds C9-N1, N1-C2, and C2-
C11 (leflunomide 1) or C12-N2, N2-C5, and C5-C3
(teriflunomide 2) in dihedral angle increments of 20°. The
conformers were further optimized in a solvation model —
conductor-like polarizable continuummodel (CPCM)—with
water as a solvent at the a) DFT/B3LYP/6-31G(d,p) and b)
DFT/B3LYP/6-311+G(d,p) level of theory [23–25].
Herein we have to add that the structural analysis of com-
pounds 1 and 2 was carried out previously [17], but the au-
thors examined only geometric arrangements of these com-
pounds and their electronic properties. In this study our atten-
tion was focused only on the 1H NMR spectra of leflunomide
1 and the interactions of teriflunomide 2 as a ligand with
selected amino acids in the enzymatic binding site.
The theoretical 1H NMR spectrum was generated for all
rotamers using the gauge-including atomic orbital (GIAO)
method [26], implemented in Gaussian G09 D.01. To show
the results more clearly, only four rotamers of the lowest en-
ergy were considered, optimized at the B3LYP/6-31G(d,p)
(conformers I–IV, Tables S1, supplementary material) and
B3LYP/6-311+G(d,p) (conformers V–VIII, Table S2, respec-
tively, supplementary material) level of theory (CPCM solva-
tion model and water as solvent). The calculated values
(Table S1 and S2) show a strong correlation with the NMR
experimental data for compound 1 [21]. Only the amide pro-
ton has a high relative error of the chemical shift, equal to
29 % at the B3LYP/6-31G(d,p)/CPCM level of theory and
to 28 % at the B3LYP/6-311+G(d,p)/CPCM level of theory.
These errors may be due to the steric effects connected
with the proximity of rotating methylisoxazole and phe-
nyl groups, proton mobility and its ability to interact
with the solvent. The use of more complex basis sets
or diffuse functions during optimization does not in-
crease the correlation between the calculated and exper-
imental values of chemical shifts. Taking into consider-
ation the accuracy of calculations as well as time and
cost required to complete them, the use of DFT/
B3LYP/6-31G(d,p)/GIAO in the NMR analysis of
rotamers of 1 seems to be a reasonable and justified
choice. It is worth mentioning that more t ime-
consuming basis (B3LYP/6-311++G(3df,2pd)/CPCM) ap-
plied for this type of calculations did not result in a
significant improvement of accuracy (Table S4,
supplementary material).
The influence of solvent on the relative error of the
chemical shift of the amide proton is supported by a sim-
ulation of the NH…H2O interactions (conformer IX, Fig. 1,
Table S3 in the supplementary material; CPCM solvation
model and water as solvent). In this case the presence of
water molecules causes a change of the N-H bond length
before and after optimization at the B3LYP/6-31G(d,p)/
CPCM level of theory by approximately 0.01 Å. It results
in a considerable decrease of the chemical shift relative
error of the amide proton to approximately 5 % and in
the formation of an N-H…O strong hydrogen contact (rN-
H=1.025 Å, dH-O=1.891 Å, θ =170.4°). It is noteworthy
that leflunomide 1–H2O adduct has a relatively high inter-
action energy, equal to -10.30 kcal mol-1 (including basis
set superposition error, BSSE) [27, 28].
The mobility of the amide proton of leflunomide 1 could
also be caused by keto-enol tautomerism and the formation of
a N=C-OH bond. To check whether this is the case, the energy
of the enol form of 1 was estimated and optimized at the
B3LYP/6-31G(d,p) level of theory (CPCM solvation model
and water as solvent) for two isomers with the hydroxyl hy-
drogen anti or syn to the C=N bond (Fig. 2a and b). The
energy difference between the enol forms (a) and (b) of 1 is
approximately 3.28 kcal mol-1. The more stable conformer is
the one with the anti hydroxyl proton (Fig. 2a). Undoubtedly,
this energy difference is partly due to a forced rotation of the
phenyl ring of the second enol form (Fig. 2b). The energy
difference between the amide form of 1 and its stable tautomer
(Fig. 2a) is approximately 17.73 kcal mol-1 at the same level of
theory. The influence of the trifluoromethyl group attached at
the phenyl ring of 1 on tautomerism is negligible. This is
because the energy difference between the enol form ana-
logues lacking the CF3 group is approximately 3.74 kcal
mol-1. On the other hand, the difference between the enol
and amide analogues of 1 without the CF3 group is approxi-
mately 18.8 kcal mol-1. These results indicate that the second-
ary amide bond of leflunomide 1 is by far a more stable one,
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despite its susceptibility to a polar solvent that can impact its
subtle electron structure.
After investigating the properties of protons of leflunomide
1, we examined their influence on the binding between
teriflunomide 2 and amino acids in the DHODH cavity as
hydrogen atoms are commonly involved in intramolecular
interactions. Docking studies showed that teriflunomide 2 in-
teracts with tyrosine Tyr356 and, through a water molecule,
with arginine Arg136 in the binding site of DHODH [16, 29].
After optimization of the teriflunomide–tyrosine adduct at the
B3LYP/6-31G(d,p)/CPCM (water as solvent) level of theory,
we found that both molecules can interact through several
hydrogen contacts.
As we havementioned in the introductory section, previous
studies on the structure of teriflunomide 2 suggested that com-
pound 2 and some of its analogues existed mainly in a Z
configuration stabilized by a strong intramolecular hydrogen
bond (Scheme 1) [30–32]. Other reports, both experimental
and theoretical, pointed out that the active form of
teriflunomide was the Z configuration lacking the internal hy-
drogen contact [14, 17]. However, there are no reports that
deal with the possibility of the E isomer formation and its
interaction with DHODH. As we have indicated above, the
exact physiological mechanism of the isoxazole ring opening
in leflunomide is not known in detail and it is possible that this
ring cleavage may provide both Z and E isomers. Besides,
these isomers can be in equilibrium via the keto form
(Scheme 1). Thus, we investigated these interactions by opti-
mization of adducts between teriflunomide 2 and tyrosine, and
both E and Z configurations were taken into consideration
even though E and Z isomers have almost identical internal
energy (-641,439.70 kcal mol-1).
In the first adduct, two hydrogen contacts were found (ad-
duct X, Fig. S1 in the supplementary material; optimization
using CPCM solvation model and water as solvent). These
contacts involve the nitrile and hydroxyl groups of
teriflunomide 2, and hydroxyl group of tyrosine; the latter
group acts as a donor and acceptor. The interaction energy
of adduct X is −10.94 kcal mol-1.
The interaction between the tyrosine hydroxyl group and
the amide proton of 2 (adduct XI, Fig. S2 in the supplemen-
tary material; optimization using CPCM solvation model and
water as solvent) results in the formation of a N-H…O type of
hydrogen contact (r=1.018 Å, d=2.038 Å, θ =173.2°). The
interaction energy of the adduct is −3.53 kcal mol-1.
In adduct XII (Fig. S3, supplementary material; opti-
mization using CPCM solvation model and water as sol-
vent) between tyrosine and teriflunomide 2, a hydrogen
bond is formed between the teriflunomide carbonyl oxy-
gen and tyrosine phenolic hydroxyl. The interaction en-
ergy is a little higher (−5.84 kcal mol-1) than that for the
previous adduct.
Fig. 1 Interaction of 1 with water molecules and formation of NH…H2O hydrogen bond (conformer IX)
105 Page 4 of 12 J Mol Model (2015) 21: 105
The above results show that the highest interaction energy
involves the hydroxyl groups of teriflunomide 2 and tyrosine
(X). This is probably due to the relatively largest partial pos-
itive charge on the hydrogen atom of the teriflunomide hy-
droxyl group that lies in the proximity of the electron with-
drawing nitrile and amide functionalities. The interaction be-
tween the nitrile group and tyrosine hydroxyl is of minor
importance because this type of hydrogen bonding is usually
classified as a weak to medium strong interaction (the sp hy-
bridization of nitrogen atom) [33]. Moreover, the calculated
angle θ (ca 135°) differs significantly from the typical angle
for H-bonded nitriles that is usually close to linearity [34].
Nevertheless, the CN…HO hydrogen bond can still improve
stability of the teriflunomide–tyrosine adduct.
Fig. 2 Tautomers of 1 with different positions (a and b) of hydroxyl groups
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The assumption concerning the contribution of the
CN…HO hydrogen contact to the overall strength of the ad-
duct is supported by the results obtained for the interaction
between tyrosine amino and teriflunomide 2 nitrile groups
(adduct XIII, Fig. S4 in the supplementary material; optimi-
zation using CPCM solvation model and water as solvent).
Here, the interaction energy is only −2.41 kcal mol-1, so it is
the lowest value from the interactions discussed above.
We also investigated the interactions of the tyrosine hy-
droxyl group with the hydroxyl and amide functionalities of
teriflunomide 2 in a Z configuration, as well as on the inter-
action of the tyrosine amine group with the nitrile function of
(Z)-teriflunomide (adducts XIV−XVI, Figs. 3 and 4, Fig. S7
in the supplementary material, Table 1; optimization using
CPCM solvation model and water as solvent).
The optimization of the adduct in which the (Z)-
teriflunomide interacts with tyrosine hydroxyl results in a con-
tact shift toward the teriflunomide carbonyl group (adduct
XIV, Fig. 3). The interaction energy between the contacting
molecules is −4.90 kcal mol-1. On the other hand, the rotation
of the teriflunomide hydroxyl group by 180°, which breaks
the intramolecular hydrogen bond, increases the interaction
energy to −7.28 kcal mol-1 (Table 1). This evidently shows
that if the intramolecular hydrogen contact existed it would
weaken the intermolecular hydrogen bond between hydroxyl
functionalities of teriflunomide and tyrosine.
The adduct XV is formed when the tyrosine hydroxyl
group interacts with the amide ni t rogen of (Z ) -
teriflunomide (the intramolecular hydrogen bond parame-
ters: O-H…O=C (r=1.019 Å, d=1.537 Å, θ=151.6 °); its
energy is equal to −7.14 kcal mol-1 (Fig. 4). The interacting
molecules are linked through two hydrogen bonds, i.e., a
hydrogen HOTyr
…NHteriflunomide contact (r=2.027 Å, d=
2.304 Å, θ =162.4°) and a weaker one between the tyrosine
hydroxyl group and nitrile π electrons (r=0.976 Å, d=
1.981 Å, θ =116.4°). The optimization of the adduct led
to lengthening of the tyrosine OH bond of 0.008 Å and an
insignificant lengthening of the teriflunomide NH bond
(0.002 Å). Reshaping of the teriflunomide hydroxyl con-
figuration resulted in cleavage of the intramolecular
OH…O=C bond and formation of a complex with the in-
teract ion energy of −19.95 kcal mol-1 (Table 1;
optimization using CPCM solvation model and water as
solvent). The teriflunomide NH bond is lengthened by
0.006 Å and linked with the tyrosine carboxyl group.
The calculated interaction energy between the tyrosine hy-
droxyl and (Z)-teriflunomide carbonyl is −3.55 kcal mol-1
(adduct XVI, Fig. S7 given in the supplementary material).
Fig. 3 Structure of the (Z)-teriflunomide 2–tyrosine adduct XIV; interaction between teriflunomide carbonyl group and tyrosine hydroxyl group
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The interacting molecules are connected through a
HOTyr
…OCteriflunomide hydrogen bond and the calculated
change in the OH bond is quite small (0.003 Å). On the other
hand, the interaction energy between the same functionalities
but with the (E)-teriflunomide contribution (without the inter-
nal hydrogen bond) is −7.67 kcal mol-1 (Table 1). The tyrosine
OH bond is lengthened by a similar value as for the Z isomer
(0.002 Å). A visible structural difference between the Z and E
Table 1 Comparison of interaction energies for adducts involving (Z) and (E)-teriflunomide 2; B3LYP/6-31G(d,p) level of theory





Adduct Interaction energy conformer
2 with internal H-bond [kcal mol-1]
Interaction energy conformer 2
without internal H-bond [kcal mol-1]
OH X −10.94 XIV −4.90 −7.28
NH XI −3.53 XV −7.14 −19.95
CO XII −5.84 XVI −3.55 −7.67
CN XIII −2.41 XVII −2.10
Fig. 4 Structure of the (Z)-
teriflunomide 2–tyrosine adduct
XV; interaction between
teriflunomide amino group and
tyrosine hydroxyl group
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isomers of teriflunomide is the spatial arrangement of the p-
trifluoromethylphenyl ring. This ring is coplanar with the am-
ide bond in the isomer Z but it is twisted from coplanarity in
the isomer E. This deviation might also influence to some
extent the strength of the intermolecular hydrogen bonding
between teriflunomide and tyrosine.
Next, we compared the interactions between the amino
group of tyrosine and nitrile of Z (adduct XVII, Fig. S8
given in the supplementary material) or E teriflunomide
(adduct XIII, Fig. S4 in the supplementary material; op-
timization using CPCM solvation model and water as
solvent). The interaction energies for both isomers is
similar and equals to −2.41 and −2.10 kcal mol-1. Thus,
the presence of the intramolecular C=O…HO hydrogen
bond does not significantly affect the strength of the
weakest interaction discussed here.
Previous studies showed that teriflunomide 2 also interacts
with arginine through a water molecule in the active site of
DHODH [30–32]. To examine whether this is a significant
feature, we optimized the adducts of compound 2 with water,
in which a single molecule of water interacted separately with
the OH, NH, and CO groups of 2. The respective BSSE
corrected interaction energy values were −14.24, −5.80, and
−4.18 kcal mol-1 (Table 2).
Moreover, we analyzed the adducts of teriflunomide 2 (E
configuration) and arginine with water participation and with
particular attention to the amino acid carboxylic group (opti-
mization using CPCM solvation model and water as solvent).
The interaction energies of the adducts XVIII−XX are
−23.95, −11.20, and −3.26 kcal mol-1, respectively (Fig. 5,
Fig. S10−S11 in the supplementary material, Table 2). The
higher value for the adduct XVIII is probably due not only to
the three hydrogen bonds, i.e., teriflunomide hydroxyl−water
−arginine hydroxyl (r=0.998 Å, d=1.685 Å, θ =175.2°) and
two teriflunomide CO−NH guanidine contacts (d1=1.015 Å,
r1=2.067 Å, θ =149.8°, as well as r2=1.012 Å, d2=2.203 Å, θ
=141.3°), but also to a quasi-ionic interaction between a pro-
tonated guanidine fragment of the amino acid and the polar-
ized amide carbonyl. The structure of the adduct is in agree-
ment with the docking studies [16, 29].
The adduct teriflunomide 2−water−arginineXIX (Fig. S10
in the supplementary material) is stabilized by two interac-
tions: a. a strong hydrogen bond between the amide NH and
arginine carboxylic group with participation of water; b. a
weak contact between the nitrile group and carboxylic
hydroxyl.
The adductXX (Fig. S11, supplementary material) with the
lowest interaction energy is, in turn, stabilized by hydrogen
bonding that involves the carboxylic group (arginine) and am-
ide carbonyl group (2) through a water molecule. The arginine
carboxylic group is linked to water through both carbonyl and
hydroxyl elements of this functionality. The interaction asso-
ciated with the carboxylic hydroxyl seems to be a weaker one
because of a comparatively longer distance d (1.933 Å). The
energy relative to the OH, NH, and CO groups of (Z)-
teriflunomide interacting with water is −11.50, −6.50, and
−1.89 kcal mol-1, respectively (Table 2). Similarly to the in-
teraction of (E)-teriflunomide with water, the weakest affinity
to water can be observed for the NH group of (Z)-
teriflunomide.
Somewhat different conclusions can be drawn from the
analysis of the adducts (Z)-teriflunomide−water−arginine
XXI−XXIII (Fig. 6, Figs. S13 and S14 in the supplementary
material, Table 2; optimization using CPCM solvation model
and water as solvent). The individual interaction energies of
arginine with the OH, NH, or CO groups of (Z)-teriflunomide
with the contribution of water are as follows: −76.70, −8.82,
or −11.59 kcal mol-1. On the other hand, the values for the
same interactions for teriflunomide with a 180° rotated hy-
droxyl group are −52.84, −9.81, and −13.01 kcal mol-1,
respectively.
Analogously to (E)-teriflunomide, the (Z) configuration of
this metabolite generates a similar set of hydrogen bonds
(XXI). A hydrogen contact is present between the hydroxyl
group of arginine and water (d=2.024 Å, r=0.972 Å, θ
=177.6°). The adduct is also stabilized by a bifurcated contact
between the guanidine residue and teriflunomide carbonyl
(r1=1.029 Å, d1=1.797 Å, θ =162.9° oraz r2=1.015 Å, d2=
2.266 Å, θ =141.3°). The almost twice lower interaction en-
ergy for the adduct (Z)-teriflunomide−arginine in comparison
Table 2 Calculated interaction energy (kcal mol-1) of (Z)- or (E)-teriflunomide (2) with arginine via water molecule – conformersXVIII−XXIII; EH2O –
interaction energy of 2 with water; E – interaction energy of 2–water–arginine adduct; B3LYP/6-31G(d,p) level of theory
Teriflunomide 2 E isomer Z isomer E isomer Z isomer
Complex 2–water 2–water–arginine








OH −14.24 −11.50 XVIII −23.95 XXI −76.70
NH −5.80 −6.50 XIX −11.20 XXII −8.82
CO −4.18 −1.89 XX −3.26 XXIII −11.59
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Fig. 5 Structure of the (E)-teriflunomide 2–water–arginine adductXVIII; interaction of arginine carboxyl group with teriflunomide hydroxyl group via
water molecule
Fig. 6 Structure of the (Z)-teriflunomide 2−water–arginine adduct XXI; interaction of arginine carboxyl group with teriflunomide hydroxyl group via
water molecule
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with the adduct that involves the E isomer is probably due to a
lower electron density of the carbonyl oxygen and lower ac-
cessibility of the hydroxyl hydrogen, both engaged in the in-
tramolecular hydrogen bond. Analyzing the data depicted in
Table 2, we can conclude that the contribution of water to the
overall interaction energy of the (Z)-teriflunomide−water
−arginine complex is higher than the analogous contribution
to the adduct involving E isomer. Thus, the E configuration is
preferred for the direct interaction teriflunomide−arginine.
Our results clearly indicate that the hydroxyl, nitrile, and
amide groups contribute to the interactions of teriflunomide 2
with arginine through water and are in agreement with the
previous reports [16, 29].
In order to prove a crucial role of the amide functionality in
the stability of teriflunomide−amino acid adduct within the
receptor cavity we carried out the quantum mechanics/
molecular mechanics (QM:MM) calculations using the
ONIOM method [35] implemented in the Gaussian software.
The human dihydroorotate dehydrogenase (DHODH) in com-
plex with a leflunomide derivative inhibitor 4 taken from the
Protein Data Bank base (3GOU.pdb) was chosen as the bio-
logical target [16, 36]. An initial target for further optimization
was prepared by removing the internal ligand from the
3GOU.pdb file ((2Z)-N-(3-chloro-2'-methoxybiphenyl-4-yl)-
2-cyano-3-hydroxybut-2-enamide, an analogue of
teriflunomide), but keeping the internal coordinates un-
changed. Then the internal ligands were replaced by the
optimized structure of 2 and additionally the residues were
saturated with hydrogen atoms. In this manner we prepared
two input models. For the low layer we chose the UFF force
field (MM calculations) [37], and for the high layer the semi-
empiric PM6 method (QM calculations) [38]. The main dif-
ference between these ONIOM models is that in the first one
all atoms are optimized, whereas in the second one only the
linking atoms as well as the QM layer undergo optimization.
The QM layer consisted of the ligand and all residues contain-
ing atoms connected with the ligand (closer than 4 Å). In the
supplementary material two inputs for the ONIOMmodels are
given. The results of our calculations are depicted in Fig. 7 and
Table 3. The outputs were visualized using the VMD package
[39]. The results of our calculations prove the importance of
the amide bond for the stability of the 2−amino acid adduct
within DHODH cavity and are in good agreement with the
experimental data involving the original receptor. This sug-
gests that the binding mode of 2 and an analogue of
teriflunomide (3GOU protein with internal ligand) are similar.
Furthermore, it seems that the E isomer of teriflunomidemight
provide a stronger teriflunomide−amino acid type of
interaction.
Conclusions
The NMR estimation proved that the amide bond of
leflunomide might be involved in the hydrogen bond forming.
Our investigations have shown that the use of more complex
basis sets or diffuse functions during optimization does not
increase the correlation between the calculated and experi-
mental values of chemical shifts. Taking into consideration
the accuracy of calculations as well as time and cost required
to complete them, the use of GIAO method in the NMR
Table 3 Calculated distances (Å) between optimized teriflunomide (2)
and corresponding amino acid within DHODH cavity; 3GOU – original
receptor DHODH taken from the PDB data base (non optimized), FMN –
flavin mononucleotide (cofactor), model 1 – first calculated (ONIOM
PM6:UFF) model (RMS=1.763), model 2 – second calculated
(ONIOM PM6:UFF) model (RMS=0.187), Tyr – tyrosine, Arg –
arginine, Pro – proline, Leu – leucine, Val – valine
Interaction 2−amino acid 3GOU Model 1 Model 2
OH…OTyr356 2.710 2.546 2.570
CN…H-Nε(Arg136) 3.499 3.106 3.076
CH3
…CH3(FMN) 4.037 3.420 4.112
CH3
…CH3(Val134) 4.006 3.615 4.037
CN…OPro52 4.100 4.853 4.128
CHphenyl
…CH3(Leu46) 3.847 3.401 3.589
F3C
…Cring(Pro364) 4.058 4.716 4.476
C=Oamide
…(H2N)2CArg136 4.308 2.862 2.823
Fig. 7 Structure of the teriflunomide 2−DHODH complex (enhanced)
optimized using ONIOM method; blue – optimized model, orange –
original structure of DHODH complex (3GOU.pdb file)
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analysis of rotamers of leflunomide seems to be the appropri-
ate choice.
The results of theoretical studies have also shown that the
interactions of teriflunomide with tyrosine and arginine in-
volve principally the amide fragment of teriflunomide. The
teriflunomide nitrile functionality is a minor contributor to
these interactions. Our calculations confirm that the presence
of the internal hydrogen bond between (Z)-teriflunomide car-
bonyl oxygen and enolic hydroxyl decreases the interaction
strength between teriflunomide and tyrosine or arginine.
Moreover, even the E isomer of teriflunomide, if ever formed
under physiological conditions, would usually provide a
stronger interaction teriflunomide−amino acid than the Z iso-
mer with the internal hydrogen bond.
Computational section
Density functional calculations were executed and the geom-
etries of compounds were optimized at the DFT level of the-
ory using the Gaussian 09 D.01 program [22], B3LYP func-
tional, 6-31G(d,p) and 6-311+G(d,p) basis set, and conductor-
like polarizable continuum model (CPCM, water as a solvent)
[23–25]. The vibrational frequencies and thermodynamic
properties were calculated by applying the ideal gas, rigid
rotor, and harmonic oscillator approximations, energy mini-
mum was confirmed by the frequency calculation for all con-
formers, no negative frequencies were detected in generated
vibrational spectrum of analyzed conformers. The conformers
were obtained by rotating the bonds C9-N1, N1-C2, and C2-
C11 (leflunomide 1) or C12-N2, N2-C5, and C5-C3
(teriflunomide 2) in dihedral angle increments of 20°, a total
of 52 conformers were obtained. NMR shielding for proton
(Href) was calculated for TMS at B3LYP/6-31G(d,p) level of
theory (CPCM solvation model and water as solvent). The
compound of interest (1) and reference compound (TMS)
were calculated using the same method, and the reference
compound was used to obtain the chemical shifts of 1 accord-
ing to the following equation: δi=σref−σi, where δi was chem-
ical shift of i-nuclei of 1, σref and σi were the calculated iso-
tropic magnetic shielding tensor for the TMS and 1, respec-
tively [18, 40]. The calculated chemical shifts for the
homotopic protons of methyl groups A or B (Scheme 1) were
averaged. The calculated chemical shifts of protons C or D
were averaged as well. Interaction energy was calculated
using counterpoise method based on the basis set superposi-
tion error (BSSE) at B3LYP/6-31G(d,p) level of theory [27,
28]. The Chemcraft 1.7 software was utilized for the visuali-
zation of all optimized conformers [41]. All ONIOM
(PM6:UFF) calculations were carried out as implemented in
the Gaussian 09 D.01 program [35]. The human
dihydroorotate dehydrogenase in complex with a leflunomide
derivative inhibitor 4, acquired from the Protein Data Bank
base (3GOU.pdb), was selected as the biological target [16,
36]. An initial target for further optimization was prepared by
removing the internal ligand from the 3GOU.pdb file (an an-
alogue of teriflunomide), but keeping the internal coordinates
unchanged. Then the internal ligands were replaced by the
optimized structure of 2 and additionally the residues were
saturated with hydrogen atoms. Two input models were pre-
pared in this manner. The outputs were visualized using the
VMD package [39]. The calculations were carried out using
resources provided by Poznan Supercomputing and Network-
ing Center (Reef cluster), as well as Wrocław Center for Net-
working and Supercomputing (Supernova cluster).
Acknowledgments The calculations were carried out using resources
provided by Poznan Supercomputing and Networking Center (PCSS
grant No. 199/2014), as well as Wrocław Center for Networking and
Supercomputing (WCSS grant No. 327/2014). The authors are indebted
to Dr. Jarosław J. Panek (Faculty of Chemistry, University of Wrocław,
Poland) for the help in the DFT and ONIOM calculations, as well as for
the manuscript correction.
Conflict of interest The authors declare no competing interest.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Kaplan MJ (2001) Curr Opin Investig D 2:222
2. Behrens F, Finkenwirth C, Pavelka K, Štolfa J, Šipek-Dolnicar A,
Thaçi D, Burkhardt H (2013) Arthritis Care Res 65:464
3. Kellner H, Bornholdt K, Hein G (2010) Clin Rheumatol 29:913
4. Kalgutkar AS, Nguyen HT, Vaz AD, Doan A, Dalvie DK, McLeod
DG, Murray JC (2003) Drug Metab Dispos 31:1240
5. McLean JE, Neidhardt EA, Grossman TH, Hedstrom L (2001)
Biochemistry 40:2194
6. O'Connor PW, Li D, Freedman MS, Bar-or A, Rice GPA,
Confavreux C, Paty DW, Stewart JA, Scheyer R (2006)
Neurology 66:894
7. Baumann P, Mandl-Weber S, Völkl A, Adam C, Bumeder I,
Oduncu F, Schmidmaier R (2009) Mol Cancer Ther 8:366
8. Zhu S, YanX,Xiang Z, Ding HF, Cui H (2013) PLoSONE 8:e7155
9. Mączyński M, Ryng S, Artym J, Kocieba M, Zimecki M, Brudnik
K, Jodkowski JT (2014) Acta Pol Pharm 71:71
10. Browne DL (2014) Angew Chem Int Ed 53:1482
11. Metro T-X, Bonnamour J, Reidon T, Sarpoulet J, Martinez J,
Lamaty F (2012) Chem Commun 48:11781
12. Dai J-J, Fang C, Xiao B, Yi J, Xu J, Liu Z-J, Lu X, Liu L, Fu Y
(2013) J Am Chem Soc 135:8436
13. Ivashkin P, Lemonnier G, Cousin J, Gregoire V, Labar D, Jubault P,
Pannecoucke X (2014) Chem Eur J 20:9514
14. Liu S, Neidhardt EA, Grossman TH, Ocain T, Clardy J (2000)
Structure 8:25
15. Leban J, Saeb W, Garcia G, Baumgartner R, Kramer B (2004)
Bioorg Med Chem Lett 14:55
J Mol Model (2015) 21: 105 Page 11 of 12 105
16. Davies M, Heikkilä T, McConkey GA, Fishwick CW, ParsonsMR,
Johnson AP (2009) J Med Chem 52:2683
17. Panek JJ, Jezierska A, Mierzwicki K, Latajka Z, Koll A (2005) J
Chem Inf Model 45:39
18. Kujawski J, Doskocz M, Popielarska H, Myka A, Drabińska B,
Kruk J, Bernard MK D2013] J Mol Struct 1047:292, and references
cited therein
19. Tukiendorf A, Nishizawa Y, Morii H, Durlach J (2007) Magnesium
intake and hepatic cancer in new perspectives in magnesium re-
search. Springer, Berlin, p 155
20. Raissi H, Mollania F (2014) Eur J Pharm Sci 56:37
21. Faragher RJ, Motto JM, Kaminski MA, Schwan AL (2003) J Label
Compd Radiopharm 46:613
22. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA,
Cheeseman JR, Scalmani G, Barone V, Mennucci B, Petersson
GA, Nakatsuji H, Caricato M, Li X, Hratchian HP, Izmaylov AF,
Bloino J, Zheng G, Sonnenberg JL, Hada M, Hada M, Ehara M,
Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y,
Kitao O, Nakai H, Vreven T,Montgomery JA Jr, Peralta JE, Ogliaro
F, Bearpark M, Heyd JJ, Brothers E, Kudin KN, Staroverov VN,
Kobayashi R, Normand J, Raghavachari K, Rendell A, Burant JC,
Iyengar SS, Tomasi J, Cossi M, Rega N, Millam NJ, Klene M,
Knox JE, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts
R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C,
Ochterski JW, Martin RL, Morokuma K, Zakrzewski VG, Voth
GA, Salvador P, Dannenberg JJ, Dapprich S, Daniels AD, Farkas
O, Foresman JB, Ortiz JV, Cioslowski J, Fox DJ (2009) Gaussian
09 D.01. Revision A.1. Gaussian Inc. Wallingford, CT
23. Becke AD (1993) J Chem Phys 98:5648
24. Lee C, Yang W, Parr RG (1988) Phys Rev B 37:785
25. Eckert F, Klamt A (2002) AIChE J 48:369
26. Wolinski K, Hinton JF, Pulay P (1990) J Am Chem Soc 112:8251
27. Boys SF, Bernardi F (1970) Mol Phys 19:553
28. Famulari A, Specchio R, Sironi M, Raimondi M D1998] J Chem
Phys 108:3296, and references cited therein
29. Giorgis M, Lolli ML, Rolando B, Rao A, Tosco P, Chaurasia S,
Marabello D, Fruttero R, Gasco A (2011) Eur J Med Chem 46:383
30. Papageorgiou C, Akyel K, Borer X, Oberer L, Rihs G (1998) Helv
Chim Acta 81:1319
31. Mahajan S, Ghosh S, Sudbeck EA, Zheng Y, Downs S, Hupke M,
Uckun FM (1998) J Biol Chem 274:9587
32. Xu F, Shen J, Mall JW, Myers JA, Huang W, Blinder L, Saclarides
TJ, Williams JW, Chong AS (1999) Biochem Pharmacol 58:1405
33. Laurence C, Brameld KA, Graton J, Le Questel J-Y, Renault E
(2009) J Med Chem 52:4073
34. Le Questel J-Y, Berthelot M, Laurence C (2000) J Phys Org Chem
13:347
35. Dapprich S, Komáromi I, Byun KS, Morokuma K, Frisch MJ
(1999) J Mol Struct (Theochem) 461–462:1
36. http://www.rcsb.org/pdb/explore/explore.do?structureId=3G0U;
Accessed July 2014
37. Rappé AK, Casewit CJ, Colwell KS, Goddard WA III, Skiff WM
(1992) J Am Chem Soc 114:10024
38. Stewart JJP (2007) J Mol Model 13:1173
39. Humphrey W, Dalke A, Schulten K (1996) J Mol Graph 14:33
40. Pierens GK (2014) J Comput Chem 35:1388
41. http://www.chemcraftprog.com; Accessed 20 Jan 2015
105 Page 12 of 12 J Mol Model (2015) 21: 105
